Cullinan Therapeutics (CGEM) Expected to Announce Earnings on Wednesday

Cullinan Therapeutics (NASDAQ:CGEM) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Price Performance

Shares of NASDAQ:CGEM opened at $7.71 on Tuesday. The company has a market cap of $455.01 million, a price-to-earnings ratio of -2.71 and a beta of -0.07. The firm has a 50 day simple moving average of $7.98 and a 200 day simple moving average of $10.23. Cullinan Therapeutics has a one year low of $6.85 and a one year high of $24.99.

Analysts Set New Price Targets

CGEM has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th. Morgan Stanley reaffirmed an “overweight” rating and set a $35.00 price target (down previously from $38.00) on shares of Cullinan Therapeutics in a research note on Friday, March 7th. Finally, UBS Group dropped their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, May 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $32.00.

Insider Activity

In related news, CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares of the company’s stock, valued at $3,673,197.13. This trade represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey Alan Jones sold 4,895 shares of Cullinan Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $41,754.35. Following the transaction, the insider now directly owns 174,164 shares of the company’s stock, valued at $1,485,618.92. This represents a 2.73% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.16% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

A hedge fund recently bought a new stake in Cullinan Therapeutics stock. Dynamic Technology Lab Private Ltd purchased a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,581 shares of the company’s stock, valued at approximately $163,000. 86.31% of the stock is owned by institutional investors and hedge funds.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.